Pharmaco-economic aspects of sipuleucel-T

Human Vaccines and Immunotherapeutics

Volumn 8, Issue 4, 2012, Pages 506-508

  Simoens, Steven ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

Cost effectiveness; Economic evaluation; Pharmaco economics; Reimbursement; Sipuleucel T

Indexed keywords

ABIRATERONE ACETATE; PLACEBO; SIPULEUCEL T; CANCER VACCINE; IMMUNOLOGIC FACTOR; TISSUE EXTRACT;

ACTIVE IMMUNIZATION; CANCER IMMUNOTHERAPY; CASTRATION RESISTANT PROSTATE CANCER; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; DRUG INDUSTRY; DRUG RESPONSE; HEALTH CARE COST; HUMAN; METASTASIS; PATIENT IDENTIFICATION; QUALITY ADJUSTED LIFE YEAR; REIMBURSEMENT; REVIEW; RISK MANAGEMENT; TERMINAL CARE; TERMINAL DISEASE; COST BENEFIT ANALYSIS; ECONOMICS; IMMUNOTHERAPY; MALE; METHODOLOGY; PROSTATE TUMOR; UNITED STATES;

CANCER VACCINES; COST-BENEFIT ANALYSIS; HUMANS; IMMUNOLOGIC FACTORS; IMMUNOTHERAPY; MALE; NEOPLASM METASTASIS; PROSTATIC NEOPLASMS; QUALITY-ADJUSTED LIFE YEARS; TISSUE EXTRACTS; UNITED STATES;

EID: 84860740362     PISSN: None     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/hv.18334     Document Type: Review

References (14)

1. US Agency for Healthcare Research and Quality. Outcomes of sipuleucel-T therapy. Available at: https://www.cms.gov/determinationprocess/downloads/ id77TA.pdf (Accessed Sept 21, 2011).
2. Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, et al.; IMPACT Study Investigators. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010; 363:411-22; PMID:20818862; http://dx.doi.org/10.1056/NEJMoa1001294.
3. Goozner M. Concerns about Provenge simmer as CMS ponders coverage. J Natl Cancer Inst 2011; 103:288-9; PMID:21303996; http://dx.doi.org/10.1093/jnci/ djr041.
4. Longo DL. New therapies for castration-resistant prostate cancer. N Engl J Med 2010; 363:479-81; PMID:20818868; http://dx.doi.org/10.1056/NEJMe1006300.
5. Hjelmgren J, Berggren F, Andersson F. Health economic guidelines - similarities, differences and some implications. Value Health 2001; 4:225-50; PMID:11705185; http://dx.doi.org/10.1046/j.1524-4733.2001.43040.x.
6. Knopf K. Sipuleucel-T immunotherapy for advanced prostate cancer. Community Oncol 2010; 7:342-4.
7. Greenberg D, Earle C, Fang CH, Eldar-Lissai A, Neumann PJ. When is cancer care cost-effective? A systematic overview of cost-utility analyses in oncology. J Natl Cancer Inst 2010; 102:82-8; PMID:20056956; http://dx.doi.org/ 10.1093/jnci/djp472.
8. National Institute for Health and Clinical Excellence. Appraising life-extending, end of life treatments. London, National Institute for Health and Clinical Excellence 2009.
9. National Institute for Health and Clinical Excellence. Update report on the application of the 'end-of-life'supplementary advice in health technology appraisals. London, National Institute for Health and Clinical Excellence 2009.
10. Chambers JD, Neumann PJ. Listening to Provenge - what a costly cancer treatment says about future Medicare policy. N Engl J Med 2011; 364:1687-9; PMID:21470004; http://dx.doi.org/10.1056/NEJMp1103057.
11. Tunis SR, Pearson SD. Coverage options for promising technologies: Medicare's 'coverage with evidence development'. Health Aff (Millwood) 2006; 25:1218-30; PMID:16966717; http://dx.doi.org/10.1377/hlthaff.25.5.1218.
12. Brower V. Approval of provenge seen as first step for cancer treatment vaccines. J Natl Cancer Inst 2010; 102:1108-10; PMID:20668267; http://dx.doi.org/10.1093/jnci/djq295.
13. Cook JP, Vernon JA, Manning R. Pharmaceutical risk-sharing agreements. Pharmacoeconomics 2008; 26:551-6; PMID:18563946; http://dx.doi.org/10.2165/ 00019053-200826070-00002.
14. Krutoholow E, Nanavati A. Dendreon unlikely to develop diagnostic despite potential to allay reimbursement fears. Financial Times Aug 29, 2011.